Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

UNCOVERED: Bofa downgrades curevac on limited 2022 prospects - Caught on Camera

There is limited upside from CureVac BV’s (NASDAQ:CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.

The CureVac Analyst: Geoff Meacham downgraded the rating for CureVac from Neutral to Underperform, while reducing the price target from $55 to $20.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.